Balefire LLC Has $2.89 Million Position in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Balefire LLC raised its holdings in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 5.3% during the first quarter, Holdings Channel.com reports. The fund owned 116,111 shares of the company’s stock after purchasing an additional 5,842 shares during the period. Fresenius Medical Care AG & Co. KGaA comprises about 1.0% of Balefire LLC’s holdings, making the stock its 26th largest holding. Balefire LLC’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $2,891,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Sanctuary Advisors LLC bought a new position in Fresenius Medical Care AG & Co. KGaA during the fourth quarter worth about $983,000. Bank of New York Mellon Corp raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 5.8% in the 4th quarter. Bank of New York Mellon Corp now owns 21,951 shares of the company’s stock valued at $497,000 after acquiring an additional 1,205 shares during the period. QRG Capital Management Inc. boosted its stake in Fresenius Medical Care AG & Co. KGaA by 16.7% during the 4th quarter. QRG Capital Management Inc. now owns 67,973 shares of the company’s stock worth $1,539,000 after acquiring an additional 9,706 shares during the last quarter. US Bancorp DE grew its holdings in Fresenius Medical Care AG & Co. KGaA by 8.6% during the fourth quarter. US Bancorp DE now owns 20,429 shares of the company’s stock valued at $463,000 after purchasing an additional 1,610 shares during the period. Finally, Smartleaf Asset Management LLC grew its holdings in Fresenius Medical Care AG & Co. KGaA by 192.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock valued at $28,000 after purchasing an additional 806 shares during the period. Institutional investors and hedge funds own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Trading Down 0.2%

Shares of Fresenius Medical Care AG & Co. KGaA stock opened at $27.74 on Thursday. The business’s 50 day simple moving average is $27.36 and its 200 day simple moving average is $24.96. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $17.93 and a 52-week high of $30.46. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.46 and a quick ratio of 1.08.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.01. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.18% and a return on equity of 6.25%. The company had revenue of $5.54 billion during the quarter, compared to analysts’ expectations of $4.71 billion. On average, equities research analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Increases Dividend

The firm also recently announced an annual dividend, which was paid on Friday, June 6th. Investors of record on Friday, May 23rd were given a $0.7871 dividend. The ex-dividend date of this dividend was Friday, May 23rd. This represents a yield of 1.9%. This is an increase from Fresenius Medical Care AG & Co. KGaA’s previous annual dividend of $0.44. Fresenius Medical Care AG & Co. KGaA’s dividend payout ratio (DPR) is 50.89%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Thursday, May 15th. Wall Street Zen initiated coverage on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, May 20th. They set a “strong-buy” rating for the company. Finally, Truist Financial boosted their price objective on shares of Fresenius Medical Care AG & Co. KGaA from $25.00 to $30.00 and gave the company a “hold” rating in a research report on Monday, May 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA currently has a consensus rating of “Hold” and a consensus target price of $27.80.

Fresenius Medical Care AG & Co. KGaA Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.